New chemo regimen aims to boost survival in kids with down syndrome and leukemia

NCT ID NCT07232134

Recruiting now Disease control Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a specific set of four chemotherapy blocks in children (0-18 years) who have both acute myeloid leukemia (AML) and Down syndrome. The goal is to see if this tailored treatment can improve long-term survival and reduce harsh side effects compared to past approaches. The trial is enrolling 100 participants across multiple centers in Russia.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: chemotherapy (cytarabine, idarubicin, etoposide, daunorubicin)
What this could lead to: If successful, this could establish a safer, more effective chemotherapy regimen for children with both AML and Down syndrome, improving survival rates and reducing toxic side effects.
What could go wrong: This is a non-randomized trial with no control group, so results may be less definitive. Chemotherapy carries significant risks like infection and organ damage, and the reduced doses might not control the leukemia as well as standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOGENOUS LEUKEMIA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia Down syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AML (ACUTE MYELOGENOUS LEUKEMIA) DOWN SYNDROME (DS)

Contacts and locations

Locations

National medical research center of pediatric haematology, oncology and immulogy named after Dmytriy Rogachyov, Moscow, 117198
RECRUITING

Moscow, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.